There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Iovance Biotherapeutics Inc. (IOVA) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.47, or -4.40%, to $10.22. Volume reached 79,530 shares, with price reaching a high of $10.34 and a low of $10. Most recently, Yahoo Finance reported about the stock as it publicized that Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer.
As a NASDAQ listed company, IOVA falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $10.03 and fluctuated between $10.77 as its day high and $10.03 as its day low. The current market capitalization of Iovance Biotherapeutics Inc. is $1.73B. A total of 2.39 million shares were traded on the day, compared to an average of 3.13M shares.
In the most recent transaction, Vogt Frederick G bought 1,000 shares of IOVA for 6.44 per share on Jun 01. After the transaction, the Interim CEO & General Counsel now owns 1,000 company shares. In a previous transaction on Jun 01, Rothbaum Wayne P. bought 500,000 shares at 6.43 per share. IOVA shares that Director owns now total 8,067,333.
Among the insiders who bought shares, Rothbaum Wayne P. acquired of 500,000 shares on May 31 at a per-share price of $6.77. This resulted in the Director holding 7,567,333 shares of IOVA after the transaction. In another insider transaction, Maynard Ryan D bought 7,500 shares at $6.75 per share on May 31. Company shares held by the Director now total 7,500.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for IOVA in the last 3 months, the mean price target is $26.38 with high estimates of $43.00 and low estimates of $13.00. In terms of 52-week highs and lows, IOVA has a high of $27.96 and a low of $6.18.
As of this writing, IOVA has an earnings estimate of $-0.64 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of $-0.56 per share and a lower estimate of $-0.7. The company reported an EPS of $-0.63 in the last quarter, which was -5% lower than expectations of $-0.6.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 14 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IOVA is Hold with a score of 4.64. A total of 10 analysts rated the stock as Buy while 2 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.